Borgeson John A. (Chief Financial Officer) sold $2.7M of stock, under a pre-arranged trading plan
SEC Form 4
Kodiak Sciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders4 buying, 1 selling84 purchases and 14 sales by directors and officers, last 12 monthsInsider trades
- Funds115 adding, 78 cuttingOf 50 active managers that changed their stake, 29 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Current signal Several insiders buying shares: 3 insiders bought shares in the open market in the past 90 days, according to their Form 4 filings.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Kodiak Sciences Inc.'s latest figures clears our strength thresholds.
Things to watch
- Results due soon. Results are expected around 12 November; the share price can move sharply on the day.
- Volatile shares. Over the past year the shares showed annualised volatility of 205% and a beta of 0.0 against the S&P 500.
- Heavily shorted. 21.4% of the shares available to trade are sold short (2.4 days of average volume to cover).
- Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.
Latest results
- Earnings per share
- -$1.05 against an average estimate of -$0.96: missed by 9.9%
- Share reaction
- -4.7% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
- Next report
- November 12, 2026; average EPS estimate -$1.01
Price chart
- 1 day-1.6%
- 1 week+9.0%
- 1 month+3.4%
- This year+249.2%
- 1 year+438.5%
- 5 years-24.0%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 13, 2026
- Next results (est.)
- November 12, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Insider trade
- Insider trade
667, L.P. (Director) bought $2.9M of stock
SEC Form 4 - Announcement
Kodiak Sciences Inc. disclosed a material event
SEC 8-KRead source ↗ - Insider trade
Baker Bros. Advisors (Gp) Llc (Director) bought $1.6M of stock
SEC Form 4 - Results
Kodiak Sciences Inc. reported results
SEC 8-KRead source ↗
No model value for Kodiak Sciences Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Next results: November 12, 2026, after the close. Analysts expect revenue of $0 and EPS of −$1.01 (range −$1.10 to −$0.89) for the quarter.
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$3.98 | +8% | — | 0% |
| Next | −$3.44 | +14% | $49m | 0% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is +6.4% on 90 days ago. In the last 30 days, 2 analysts raised Kodiak Sciences Inc.'s forecast and 0 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$3.74 | −$3.12 |
| 60 days ago | −$3.99 | −$3.75 |
| 30 days ago | −$3.99 | −$3.75 |
| 7 days ago | −$3.98 | −$3.44 |
| Now | −$3.98 | −$3.44 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.96 | −$1.05 | −9.9% |
| Mar 2026 | −$1.01 | −$0.94 | +7.1% |
| Dec 2025 | −$1.05 | −$1.04 | +1.2% |
| Sept 2025 | −$1.04 | −$1.16 | −11.5% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 21.4% of tradable shares
- Days to cover
- 2.38 at average volume
- Short interest, 1 month
- −20% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 5.2% of shares
- Employees
- 141 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| KOD | −42% | −92% | −58% | +227% | +181% | +249% |
| Industry peers (median) | −35% | −56% | −17% | −29% | −5% | −27% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| KOD | 50% | 42% | 42% | 58% | 67% | 64% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| KOD | −53% | −94% | −85% | −71% | −79% | −36% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since October 4, 2018: 99% from January 19, 2021 to October 25, 2023. Getting back needed a 11648% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $16.90 – $100.40
- From 52-week high
- −2.8%
- vs 50-day average
- +50.4%
- vs 200-day average
- +130.0%
- Volatility (1 year)
- 205%
- Beta vs S&P 500
- 0.02
Share price after results
- Next day
- 4 up, 8 down typical move ±11.8%
- After a week
- 5 up, 7 down typical move ±16.2%
- After a month
- 7 up, 5 down typical move ±29.8%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 13, 2026 | −4.7% | +0.5% | −8.2% | −23.7% |
| May 7, 2026 | −10.6% | +0.5% | −15.7% | −35.5% |
| March 31, 2026 | +27.2% | +3.7% | +24.2% | +29.2% |
| November 13, 2025 | −3.7% | −1.7% | −3.3% | +13.7% |
| August 13, 2025 | +17.8% | +0.4% | +11.5% | +8.6% |
| May 14, 2025 | −17.4% | +0.6% | −12.2% | −3.7% |
| March 27, 2025 | −3.3% | −2.3% | −20.3% | +39.9% |
| November 14, 2024 | +0.5% | −1.9% | +7.3% | +47.6% |
| August 14, 2024 | −1.1% | +2.0% | +6.5% | +3.4% |
| May 15, 2024 | −2.6% | +1.0% | −15.1% | −26.8% |
| March 28, 2024 | −40.3% | −0.2% | −44.7% | −54.8% |
| November 14, 2023 | +12.2% | +2.2% | +25.0% | +71.1% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $2.4B
- Institutions reporting
- 199
- Shares held vs prior quarter
- ▲ 4.3%
- Positions opened / closed
- 34 / 23
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Baker Bros. Advisors LP | $776M | 19.9M | 32.9% | 0.0% |
| Blackrock, Inc. | $161M | 4.1M | 6.8% | ▲ 5.1% |
| Price T Rowe Associates Inc | $127M | 3.2M | 5.4% | ▲ 59.3% |
| State Street Corp | $94.3M | 2.4M | 4.0% | ▲ 7.5% |
| Goldman Sachs Group Inc | $90.2M | 2.3M | 3.8% | ▲ 37.1% |
| Vanguard Capital Management LLC | $70.3M | 1.8M | 3.0% | ▲ 5.1% |
| Braidwell LP | $69.6M | 1.8M | 3.0% | ▼ 1.7% |
| Jupiter Topco LLC | $59.5M | 1.5M | 2.5% | — |
| RTW Investments, LP | $58M | 1.5M | 2.5% | 0.0% |
| Boxer Capital Management, LLC | $57.6M | 1.5M | 2.4% | ▲ 8.6% |
| T. Rowe Price Investment Management, Inc. | $57.5M | 1.5M | 2.4% | ▲ 76.5% |
| Tcg Crossover Management, LLC | $56.3M | 1.4M | 2.4% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Kodiak Sciences Inc.'s complete shareholder register. Values are as reported by the filers ; 1 inconsistently scaled filing rows were excluded.
Insider trading activity
Full insider history and chart Insider purchases History → $217M 84 trades by 4 insiders, last 12 months Insider sales History → $4.9M 14 trades by 1 insider · 100% under pre-set plans
Net ▲ $212M net buying
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 100 | $94.91 | $9,491 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 2,000 | $93.71 | $187,420 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 2,000 | $92.66 | $185,320 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 2,985 | $91.76 | $273,904 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 5,101 | $90.98 | $464,089 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 7,623 | $89.74 | $684,088 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 1,677 | $89.20 | $149,588 |
| Borgeson John A. Chief Financial Officer | October 21, 2026 | Sell pre-set plan | 8,514 | $87.67 | $746,422 |
| 667, L.P. Director | September 29, 2026 | Buy | 84 | $85.89 | $7,215 |
| 667, L.P. Director | September 29, 2026 | Buy | 20,031 | $85.40 | $1.7M |
| 667, L.P. Director | September 29, 2026 | Buy | 1,195 | $85.40 | $102,053 |
| 667, L.P. Director | September 29, 2026 | Buy | 10,381 | $84.24 | $874,495 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Trades by members of Congress
All 2 trades and filingsNo trades in Kodiak Sciences Inc. disclosed in the last 12 months; 2 earlier trades on record.
- Chris JacobsSale (full), $1,001 - $15,000, traded November 8, 2022, filed December 12, 2022
- Chris JacobsPurchase, $1,001 - $15,000, traded July 18, 2022, filed September 9, 2022
Earnings dates and SEC filings
Results announcements
Next expected around November 12, 2026 estimated from the company's past filing pattern, not announced
- August 13, 2026
- May 7, 2026
- March 31, 2026
- November 13, 2025
- August 13, 2025
- May 14, 2025
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- DEF 14A Proxy statement
- 10-K Annual report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Kodiak Sciences Inc. in brief
- What does Kodiak Sciences Inc. do?
- Kodiak Sciences Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Kodiak Sciences Inc.'s stock ticker?
- Kodiak Sciences Inc. trades under the ticker KOD on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Kodiak Sciences Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Baker Bros. Advisors LP, Blackrock, Inc. and Price T Rowe Associates Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Kodiak Sciences Inc. stock?
- Over the last 12 months, Kodiak Sciences Inc.'s directors and officers reported 84 open-market purchases and 14 sales on Form 4. The insider trading page charts every trade.
- When is Kodiak Sciences Inc.'s next earnings date?
- Around November 12, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Kodiak Sciences Inc. announces its own schedule.
Follow research on Kodiak Sciences Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.